Reneo Pharmaceuticals, Inc. announced the appointments of Michael P. Cruse to the role of Chief Operating Officer and Jennifer P. Lam to the role of Principal Financial and Accounting Officer. Mr. Cruse has over 20 years of operational experience and has held roles of increasing responsibility at Reneo Pharmaceuticals, Eldon Pharmaceuticals (formerly Novus Therapeutics) and Avanir Pharmaceuticals (acquired by Otsuka Pharmaceuticals). Mr. Cruse most recently served as Senior Vice President of Corporate Operations at Reneo Pharmaceuticals.

In his expanded role, which is effective immediately, Mr. Cruse will oversee finance and administration, human resources, legal and compliance, corporate operations, and commercial development. Ms. Lam has over 25 years of experience, including finance and accounting roles at Reneo Pharmaceuticals, Amplyx Pharmaceuticals (acquired by Pfizer), Dendreon Corporation (acquired by Sanpower Group), Horizon Pharma, Lumena Pharmaceuticals (acquired by Shire), IDM Pharma (acquired by Takeda), and Ernst and Young, LLP. Ms. Lam currently serves as Vice President of Finance and Accounting at Reneo Pharmaceuticals.

In her expanded role, which will become effective at month-end, Ms. Lam will oversee accounting, financial reporting, financial planning and analysis, and administration.